GPTZero to be Acquired by Superhuman
Cooley advised GPTZero, a leading AI content detector with a comprehensive authenticity suite, on its agreement to be acquired by Superhuman, the productivity platform bringing AI to wherever people work. GPTZero to be Acquired by Superhuman
First Street Acquired by MSCI
Cooley advised First Street, a leading provider of physics-based climate risk data and analytics for every property in the world, on its agreement to be acquired by MSCI for $120 million in cash at closing, with the potential for additional cash payments during the first two years following closing if […]
CRED Receives Significant Investment From Meta
Cooley advised CRED, an Indian fintech startup, on its $900 million investment from Meta at a $4.5 billion post-money valuation. The investment gives Meta a roughly 20% stake in CRED, with plans to appoint its founder, Kunal Shah, the new leader of WhatsApp. CRED Receives Significant Investment From Meta
Fin to be Acquired by Salesforce for Approximately $3.6 Billion
Cooley advised Fin, formerly Intercom, an industry-leading customer agent company, in its agreement to be acquired by Salesforce, the global leader in CRM, for approximately $3.6 billion. Fin to be Acquired by Salesforce for Approximately $3.6 Billion
Cooley Advises ZincFive on DeSPAC Transaction With Spark I Acquisition Corp
Cooley advised ZincFive, the leader in immediate power solutions for the data center and artificial intelligence infrastructure markets powered by its proprietary nickel-zinc battery technology, on its definitive business combination agreement with Spark I Acquisition Corporation (Nasdaq: SPKL), a special purpose acquisition company formed by SparkLabs Group. This proposed transaction represents […]
Avenzo Therapeutics to be Acquired by Rallybio
Cooley advised Avenzo Therapeutics, a clinical-stage biotechnology company developing next-generation oncology therapies, on its agreement to be acquired by Rallybio, a clinical-stage biotechnology company. Avenzo Therapeutics to be Acquired by Rallybio
Curevo Vaccine to be Acquired by Eli Lilly for up to $1.5 Billion
Cooley advised Curevo Vaccine, a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, on its proposed acquisition by Eli Lilly and Company for up to $1.5 billion. Curevo Vaccine to be Acquired by Eli Lilly for up to $1.5 Billion
Vaccine Company to be Acquired by Eli Lilly for up to $1.5 Billion
Cooley advised Vaccine Company, a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, on its agreement to be acquired by Eli Lilly for up to $1.5 billion. Vaccine Company to be Acquired by Eli Lilly for up to $1.5 Billion
Engage Bio Acquired by Eli Lilly for up to $202 Million
Cooley advised Engage Bio, a preclinical biotechnology company pioneering non-viral DNA delivery, on its acquisition by Eli Lilly for up to $202 million in cash, including an upfront payment and subsequent payments upon achievement of specified development milestones. Engage Bio Acquired by Eli Lilly for up to $202 Million
Orphai Therapeutics Sale to Quince Therapeutics
Cooley advised Orphai Therapeutics, a clinical-stage biotechnology company, on its sale to Quince Therapeutics, a biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. The acquisition brings Orphai’s lead program LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), to treat rare […]